BioMarker Strategies, LLC, a private company, has developed SnapPath®, a cancer diagnostics system that automates and standardizes functional ex vivo profiling of live solid tumor cells from fresh biopsies or other fresh, unfixed samples such as xenografts or tumorgrafts, according to the company’s website (see here: www.BioMarkerStrategies.com). SNNLive spoke with Jerry Parrott, President and CEO of BioMarker Strategies at the BioMaryland Booth at BIO International 2015 in Philadelphia, PA.
Mr. Parrott begins with a brief overview of the Company, “We were founded to solve a problem that exists only with solid tumor cancers, and that is that most of the biomarker tests that are used to test these cancers are based on dead fixed tissue samples, and when you process these samples, you lose all the dynamic information available from cells when they are alive. So, we have a platform that makes it possible to keep these cells alive, test them while they are alive, and capture the dynamic information – its much more predictive of acquired mechanisms of resistance and helps you know which patients will do well on a particular targeted therapy and which will not.”
Mr. Parrott goes on to discuss the diagnostics market, his background, what the Company is looking to do with their platform technology, BioMarker Strategy’s business model, and his insight for the Company moving forward. He concludes with why the Company works in Maryland.
For more information about BioMarker Strategies, LLC, go to: www.BioMarkerStrategies.com
© 2017 Stock News Now
Supported by Superior Web Solutions